09 Apr Pseudoephedrine-containing Medicines Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS) – J&J
Posted at 09:03h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Johnson and Johnson (Pty) Ltd would like to inform you about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
27/05/2024
File Type:
pdf
Category:
Communication To Health Care Professionals